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When cultured porcine aortic endothelial cells (ECs) were incubated with porcine bigendothelin-I (bit ET-I ,_39), there was a time-dependent increase 
in immunorcactive (IR)-ET in the culture supernatant. in addition to an endogenous IR-ET release fron the cells. Reverse-phnt: HPLC of thcculture 
supcrnatant revealed one major JR-ET component corresponding to the elution position of synthetic ET-I, thereby indicating that the additional 
increase in IR-ET was due to the conversion of big ET-I to mature ET-I ,_?,. Phosphoramidon. a metalloproteinasc inhibitor. strongly supprcsscd 
this increase in [R-ET as well as the endogenous IR-ET release. Cultured vascular smooth muscle cells (VSMCs) also released IR-ET. The apparent 
conversion of exogenously applied big ET-I to ET-I and its inhibition by phosphoramidon were observed using cultured VSMCs, although the 
enzyme inhibitor did not influence the basal secretion of IR-ET from VSMCs. These results suggest that both cultured ECs and VSMCs can generate 
ET-I from exogenously applied big ET-I via action of the same type of phosphoramidon-sensitive metalloproteinasc. which is also involved in the 
endogenous ET-I generation in ECs. 
Endothelin-I: Big cndothelin-I: Mctalloproteinase; Phosphoramidon; Endothclial cell; Vascular smooth muscle cell 
1. INTRODUCTION 
Endothclin- I (ET- 1, ?,) is produced from a 39-amino 
acid intermediate form, tested big ET-I. through an 
unusual proteolytic processing at the Trp2’-Val” bond 
by a putative ET converting enzyme (ECE) [ 11, Several 
types of proteinases have been reported to cleave the 
Trp”-Val” bond in the big ET-I molecule. We [2,3] 
and others [4] noted that cathepsin D-like aspartic 
proteinase may be involved in the conversion of big 
ET-I in vascular endothelial cells (ECs). However, since 
cathepsin D cleaves not only the Trp”-Val’” bond but 
also the Asp”‘-Ile ” bond [5,6], the physiological re- 
levance of the conversion by this type of enzyme is 
unclear. We obtained evidence for the presence of phos- 
phoramidon-sensitive metalloproteinase which exists in 
a membrane-bound form and can convert big ET-I to 
ET-I via a single cleavage between Trp” and Val’“. in 
cultured vascular ECs 171. Furthermore, we found that 
phosphoramidon caused a decrease in ET-I secretion 
and an increase in big ET-I secretion from cultured 
ECs, as a result of the inhibition of ECE by phosphora- 
midon [83. These findings strongly suggest that phos- 
phoramidon-sensitive metalloproteinase is responsible 
for the conversion of big ET-1 in vascular ECs. 
In the present study. we examined whether intact cul- 
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tured ECs and vascular smooth muscle cells (VSMCs) 
can convert exogenously applied big ET- 1 to the mature 
ET-I. Since results clearly revealed the generation of 
ET-I from exogenous big ET-l in both species of cells, 
we evaluated the effect of phosphoramidon on this gen- 
eration of ET-I, and the effect was compared with that 
on endogenous ET-l generation in cell species. 
2. MATERIALS AND METHODS 
2.1 , Cell cdrm? 
ECs and VSMCs isolated from fresh porcine thoracic aortas were 
cultured as described [Q, IO]. The cells (S-10 passages) grown in 60-mm 
Petri dishes (ECs, about IO” cells: VSMCs, about 2 x 1Oh cells) were 
incubated with 3 ml of strum-free Dulbecco’s modified Eagle’s mc- 
dium containing 0.01% heat-inactivated bovine serum albumin. in the 
absence or presence of phosphoramidon (lOeJ M) and big ET-I (70 
pmol). at 37°C in CO2 incubator for 3-24 II. After the incubation, 
medium was aspirated off. boiled for 5 min, and the preparation was 
centrifuged iit SO00 x g for 5 min. The resulting supcrnatant served 
as sample for the radioimmunoassay (RIA) and reverse-phase high 
performance liquid chromatography (RP-HPLC). Phospkoramidon 
was purchased from Peptide lnstitutc Inc. (Osaka. Japan), 
RlAs for ET and the C-tcnninal fragment (CTF1& of big ET-I 
wcrc performed as described [2,3]. ET-I antiserum (a gcncrous gift 
from Dr M.R. Brown, Dcpartmcnt ofMcdicinc. UnivcrsityofCalifor- 
nia, San Diego) did not cross-react with big ET-I. as described [I I]. 
Antiserum to the CTF (Pcptidc Institute Inc.. Osaka. Japan) had a 
100% cross-reactivity with big ET-I and no cross-reactivity with ET-I. 
About 5 ml of culture supcrnatant after incubation for 12 h (ECs) 
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or 24 h (VSMCs). with or without big ET-I and phosphoramidon. was 
applied to a Sep-Pak C,, cartridge (Waters. MA). The adsorbed mate- 
rials were elutcd with 3 ml of602 CH&N in 0.09% trifluoroaccticacid 
(TFA). and evaporated in a centrifugal concentrator. The residual 
materials were dissolved in 0.5 ml of 0.02% TFA and 0.4 ml portions 
were then applied on a Capcell-Pak SC,@Zi300 column (4.6 x 250 
mm, Shiseido, Tokyo, Japan) using a Waters HPLC system (Model 
6OOE). Elution was performed using 0.02% TFA in water (solvent A) 
and 0.02% TFA in CH$ZN (solvent B). The gradient consisted of a 
linear one from O-35 vol./val.% solvent B for I5 min. followed by 
isocratic elution at 35 voi./vol.% solvent B for IS min and a linear 
gradient from 35-63 vol./vol.% solvent Bfor I5 min. The flow rate was 
0.5 ml/min. Each fraction was evaporated and assayed for immunore- 
active (IR)-ET by RIA. 
2.4. Peprides 
Synthetic porcine ET-I,.,, and big ET-IIm3,, were obtained from 
Peptide Institute Inc. (Osaka. Japan). The CTFIZ_>,, was prepared by 
solid phase synthesis. The homogeneity was confirmed by RP-HPLC 
and by amino acid analysis. 
3. RESULTS AND DISCUSSION 
Cultured ECs released IR-ET and IR-CTF in a time- 
dependent manner (2.65 -t 0.18 pmol of IR-ET/IO” cells/ 
24 h and 3.05 2 G.20 pm01 of IR-CTF/lO” cells/24 h. 
respectively). and the amount of IR-ET was markedly 
decreased by phosphoramidon (IO-” M). As described 
earlier [8]. the decreased release of IR-ET observed with 
phoaphoramidon is probably due to inhibition of ECE 
by the agent. 
When the cells were incubated with synthetic big ET- 
1 (70 pmoll106 cells), a time-dependent additional in- 
crease in IR-ET in medium was observed (Fig. 1). With 
incubation for 12 h, the increase in IR-ET was 0.60 ? 
0.07 pmol/lO’ cells. Consistent with the case of endoge- 
12 hr 
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Fig. I. Changes in IR-ET cantCnt io culture tncdiun~ of KS after 
incubation with or without phosphoramidon (IO-” M) for 3.12 h: 
(Hatched column) IR-ET content in the abscncc of the cxogcnoua 
application of synthetic big ET-I (ct~dogc~~o~s IR-ET iclcasc): (open 
column) additional incrcasc in [R-ET by 111~ cxogcnous application 
ofsynthetic big ET-l. Values rcprcscnt the 1nc;111 + SE from 7 scparatc 
expcrimcnts. 
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Fig. 2. RP-HPLC profiles of IR-ET in culture medium of ECs. ECs 
were incubated in the absence (c) or presence (0) of synthetir big ET-I 
for I? h. Arrow indicates the elution position of ET-l. 
nous IR-ET release. phosphoramidon remarkably sup- 
pressed (80-90%) the IR-ET increase by exogenous ap- 
plication of big ET-l. 
Using RP-HPLC coupled with RIA for ET, we ex- 
amined the IR-ET in the culture medium. with or with- 
out exogenous big ET-1 application. As shown in Fig. 
2, in both cases. the RP-HPLC profiles clearly revealed 
one major IR-ET component corresponding to the elu- 
tion position of synthetic ET-l. thereby indicating that 
the additional increase in IR-ET by exogenous big ET-1 
application, as well as the endogenous release of IR-ET. 
are due to production of the mature ET-I. Phosphora- 
midon is likely to suppress ET-I production in both 
cases by inhibiting the conversion of big ET- 1 to ET-l. 
Only a small fraction of exogenously added big ET-1 
can be converted to the mature ET-I. When incubating 
70 pmol big ET-l with 10” cells for 12-24 h, l-2% of 
the added big ET- 1 was converted to ET- I. On the other 
hand, with the same cultured cells and under the same 
conditions, the ratio of the amount of endogenously 
released ET- 1 and big ET- 1 was 4-9: 1 on a molar basis 
[3,8]. If exogenously added big ET-l is converted to 
ET- 1 in the same manner as the endogenously generated 
big ET-1 is processed to the mature ET-l. 80-90% of 
the added big ET-l would be converted to ET-I. By way 
of explanation, we assume that generation of endoge- 
nous ET-1 is an intracellular cvcnt. whereas the conver- 
sion of exogenously added big ET-I is an extracellular 
one (probably via the action of ectoenzyme). Alterna- 
tively. if part of the added big ET-I can enter the cell, 
a small amount of big ET-l may bc converted to ET-l 
by an intracellular processing enzyme. followed by the 
release of generated ET-1 into the extracellular .spacc. 
In addition. based on the assumption that cndogcnously 
generated big ET-1 is converted to ET-1 by an intraccl- 
lular cnzytuc. the ECE inhibitor phosphoramidon 
would pcnctrutc the plasma mcmbranc of KS. Further 





Fig. 3. Changes in IR-ET content in culture medium of VSMCs after 
incubation with or without phosphoramidon (IOmJ M) for 3-24 h: 
(Hatched column) IR-ET content in the abscncc of the exogenous 
application of synthetic big ET-I (endogcnous IR-ET release): (open 
column) additional increase in IR-ET by the exogenous application 
of synthetic big ET-I. Values represent the mean + SE from 10 sepa- 
rate experiments. 
studies are underway to clarify the precise mechanisms 
and sites for the conversion of big ET-1 in ECs. 
We also measured the amount of IR-ET and IR-CTF 
accumulating in culture medium of VSMCs. Cultured 
VSMCs released IR-ET and IR-CTF in a time-depend- 
ent manner (0.10 + 0.01 pmol of IR-ET/IO” cells/24 h 
and 0.21 rt. 0.02 pmol of IR-CTF/lOG cells/24 h, respec- 
tively), although the amounts released were considera- 
bly lower than those seen with cultured ECs. In contrast 
to the case of ECs. the IR-ET release from cultured 
VSMCs was not influenced by phosphoramidon. As 
shown in Fig. 3. when cultured VSMCs were incubated 
with synthetic big ET-1 (70 pmolR x 10” cells), the 
amount of IR-ET in the culture supernatant was mark- 
edly increased, in a time-dependent manner. During 
incubation for 24 h with big ET-l, the observed increase 
in IR-ET was 0.81 a 0.08 pmol/lOh cells. Unlike the 
endogenous release of IR-ET, phosphoramidon sup- 
pressed (85-95% inhibition) the increases in IR-ET ob- 
served by the exogenous application of big ET-l. Anal- 
ysis of the culture supernatant of VSMCs incubated 
with exogenous big ET-l by RP-HPLC revealed one 
major IR-ET component corresponding to the clulion 
position of synthetic ET-l. In the cast of the culture 
supcrnatant in the presence of phosphoramidon, ;L nota- 
blc decrease in ET-l-like materials was observed (Fig. 
4). These results strongly suggest that cxogcnously 
added big ET-l is convcrtcd to the mature ET-1 by 
phosphoramidon-stnsitivc cnzymc. similar to cvcnts 
seen with ECs, On the other hand. the IR-ET rclcasc 
from cultured VSMCs in the absence of big ET-1 wits 
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Fig. 4. RP-HPLC profiles ot‘ IR-ET in culture medium of VSMCs. 
VSMCs were incubated with (0) or without (0) phosphoramidon (IO-J 
M). in the presence of synthetic big ET-I for 24 h. Arrow indicates the 
elution position of ET-I. 
not influenced by phosphoramidon, thereby suggesting 
that endogenous ET-l generation in cultured VSMCs is 
mediated by phosphoramidon-insensitive enzyme(s). 
Most recently, we noted that the membrane fraction of 
VSMCs contains 2 types of metalloproteinases, which 
convert big ET-l to the mature ET-l [lo]; one is phos- 
phoramidon-sensitive and the other is phosphora- 
midon- insensitive. However, since the amount of IR- 
ET released endogenously from cultured VSMCs was 
minute (about 3% of that from cultured ECs), the phy- 
siological significance of the insensitivity to phosphora- 
midon remains to be explored. 
Resink et al. [12] stated that cultured VSMCs can 
express ETmRNA and secrete ET-l-like materials. 
They proposed an autocrine regulatory mechanism of 
the action for ET-l in addition to the known paracrine 
function of ET-l in the vasculature. in the present 
study, we found that both cultured ECs and VSMCs can 
generate mature ET-l from exogenously applied big 
ET-l, via the action of phosphoramidon-sensitive me- 
talloproteinase, which is also involved in the endoge- 
nous ET-l generation in ECs [S]. We [13] and others 
[ 14,151 noted that the big ET-l-induced hypertensive 
action (probably by conversion to ET-l) is effectively 
inhibited by phosphoramidon. Moreover, we [16] ob- 
tained evidence that both the pressor response and the 
increase in 1 R-ET observed during perfusion of big ET- 
1 in isolated rat mesenteric artery were markedly sup- 
pressed by phosphoramidon. Taken together, phospho- 
ramiclon-sensitive metalloproteinase(s) in both ECs and 
VSMCs seems to be responsible for the local generation 
of ET- 1, putatively related to pathophysiological rcgu- 
lation of the cardiovascular system. 
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